CVS Health reported mediocre first quarter results, missed analyst's expectations and lowered guidance for fiscal 2024. However, CVS Health might actually profit from a struggling competitor Walgreens Boots Alliance and is certainly the better investment in my view. The stock remains deeply undervalued and a reversion to the mean is likely.
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
While CVS Health (CVS) has been grappling with the pharmacy reimbursement pressure, a turnaround might be in the cards given its several strategic initiatives.
CVS Health's stock plummeted 17% after disappointing Q1 results, partially due to increased medical costs and lower than expected earnings. CVS and Walgreens have different business models, with CVS focusing on health services and benefits, while Walgreens relies heavily on retail pharmacy operations. Despite short-term headwinds, CVS's solid balance sheet, dividend yield, and diversified business model make it a reasonable buy for investors seeking passive income.
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CVS Health isn't delivering strong financial results. The company's issues will linger for at least a little longer.
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CVS Health Corporation ("CVS" or "the Company") (NYSE:CVS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
CVS Health stock (NYSE: CVS) currently trades at $58 per share, 47% below its pre-inflation shock high of $110 seen in February 2022. In contrast, its peer – Walgreens stock – is down 75% over this period, amid falling profitability.